Merz Therapeutics GmbH vs. Viatris Sante
UPC_CFI_697/2025
Case Details
Parties & Representative
Claimants
Represented By
1 Representative ListedRepresentative
Court & Judges
Court / Division
Paris (FR) Local Division
Judges
Camille Lignieres
Carine Gillet
Samuel Granata
Rainer Friedrich
Docket Entries
Exhibit No. 401 - Goodman Poster
2025-07-31
No Actions
Exhibit No. 007 - DE Commercial Register - Merz Therapeutics GmbH
2025-07-31
No Actions
Exhibit No. 507 - Article L. 138-9
2025-07-31
No Actions
Exhibit No. 011 - Viatris Generics webpage
2025-07-31
No Actions
Exhibit No. 131 - FAMPYRA French Price Notice 04.06.2025
2025-07-31
No Actions
Exhibit No. 210 - French
2025-07-31
No Actions
Exhibit No. 201 - French
2025-07-31
No Actions
Exhibit No. 605 - CoA Sumi Agro v Syngenta 3.03.2025
2025-07-31
No Actions
Exhibit No. 104 - Lublin - Reingold 1996
2025-07-31
No Actions
Exhibit No. 501 - 2021 Health Products Agreement
2025-07-31
No Actions
Exhibit No. 106 - Larocca 2011
2025-07-31
No Actions
Exhibit No. 213 - French
2025-07-31
No Actions
Exhibit No. 126 - Reply Letter 2.07.2025
2025-07-31
No Actions
Exhibit No. 209 - French
2025-07-31
No Actions
Exhibit No. 501 - 2021 Health Products Agreement
2025-07-31
No Actions
Exhibit No. 204 - Merz GmbH and Merz France Short Form Sub-Licence
2025-07-31
No Actions
Exhibit No. 001 - Merz History webpage
2025-07-31
No Actions
Exhibit No. 302 - EPO T 0421.14 Decision
2025-07-31
No Actions
Exhibit No. 402 - Goodman Slideshow
2025-07-31
No Actions
Exhibit No. 125 - Notice Letter 18.06.2025
2025-07-31
No Actions
Exhibit No. 114 - FAMPRIDINE VIATRIS SmPC
2025-07-31
No Actions
Exhibit No. 006 - Merz - Acorda Asset News
2025-07-31
No Actions
Exhibit No. 510 - Order Pharmacists-Health Insurance- 31.03.2022
2025-07-31
No Actions
Exhibit No. 201 - French
2025-07-31
No Actions
Exhibit No. 123 - Weekly GERS Fampridine Sales
2025-07-31
No Actions
Exhibit No. 503 - Toumi et al. External Reference Pricing Simulation
2025-07-31
No Actions
Exhibit No. 108 - FAMPYRA SmPC
2025-07-31
No Actions
Exhibit No. 203 - Merz LLC and Merz GmbH Short Form Licence
2025-07-31
No Actions
Exhibit No. 131 - FAMPYRA French Price Notice 04.06.2025
2025-07-31
No Actions
Exhibit No. 202 - Official Intellectual Property Bulletin 25.13
2025-07-31
No Actions
Exhibit No. 128 - Reply Letter 10.07.2025
2025-07-31
No Actions
Exhibit No. 600 - LD Dusseldorf Valeo v Magna 31.10.2024
2025-07-31
No Actions
Exhibit No. 504 - LEEM 2021 Economic Extracts
2025-07-31
No Actions
Exhibit No. 109 - FAMPYRA EPAR Summary
2025-07-31
No Actions
Exhibit No. 012 - Viatris France webpage
2025-07-31
No Actions
Exhibit No. 129 - FAMPYRA French Reimbursement Order 02.06.2025
2025-07-31
No Actions
Exhibit No. 206 - French
2025-07-31
No Actions
Exhibit No. 509 - Substituting Generic Product on Ameli
2025-07-31
No Actions
Exhibit No. 118 - French
2025-07-31
No Actions
Exhibit No. 607 - CoA 10x Genomics v NanoString 26.02.2024
2025-07-31
No Actions
Exhibit No. 512 - Performance-Based Remuneration
2025-07-31
No Actions
Exhibit No. 008 - FR Commercial Register - Merz Pharma France
2025-07-31
No Actions
Exhibit No. 124 - Monthly GERS Fampridine Sales
2025-07-31
No Actions
Exhibit No. 103 - Lucchinetti et al. 2000
2025-07-31
No Actions
Exhibit No. 512 - Performance-Based Remuneration
2025-07-31
No Actions
Exhibit No. 500 - Notice Amendment Generic Distribution- 6.01.2006
2025-07-31
No Actions
Exhibit No. 117 - French
2025-07-31
No Actions
Exhibit No. 508 - Ceilings for Discounts Decree
2025-07-31
No Actions
Exhibit No. 120 - French
2025-07-31
No Actions
Exhibit No. 012 - Viatris France webpage
2025-07-31
No Actions
Exhibit No. 112 - FAMPYRA EU Definitive Approval
2025-07-31
No Actions
Exhibit No. 129 - FAMPYRA French Reimbursement Order 02.06.2025
2025-07-31
No Actions
Exhibit No. 003 - Merz Therapeutics website
2025-07-31
No Actions
Exhibit No. 209 - French
2025-07-31
No Actions
Exhibit No. 504 - LEEM 2021 Economic Extracts
2025-07-31
No Actions
Exhibit No. 510 - Order Pharmacists-Health Insurance- 31.03.2022
2025-07-31
No Actions
Exhibit No. 008 - FR Commercial Register - Merz Pharma France
2025-07-31
No Actions
Exhibit No. 505 - CFIEC T-114.06 R 20.07.2006
2025-07-31
No Actions
Application for provisional measures
2025-07-31
No Actions
Exhibit No. 606 - LD Munich 10x Genomics v NanoString 19.09.2023
2025-07-31
No Actions
Exhibit No. 200 - French
2025-07-31
No Actions
Exhibit No. 004 - Acorda Bankruptcy Proceedings and Liquidation Plan
2025-07-31
No Actions
Exhibit No. 119 - French
2025-07-31
No Actions
Exhibit No. 212 - Acorda and Merz LLC Short Form Assignment
2025-07-31
No Actions
Exhibit No. 502 - Kanavos et al. External Reference Pricing Implementation
2025-07-31
No Actions
Exhibit No. 301 - Federal Patent Court Decision
2025-07-31
No Actions
Exhibit No. 122 - French
2025-07-31
No Actions
Exhibit No. 604 - CoA Biolitec v Light Guide 24.02.2025
2025-07-31
No Actions
Exhibit No. 119 - French
2025-07-31
No Actions
Exhibit No. 208 - French
2025-07-31
No Actions
Exhibit No. 130 - FAMPYRA French Public Institution Approval Order 02.06.2025
2025-07-31
No Actions
Exhibit No. 005 - US Commercial Register - Merz Pharmaceuticals LLC
2025-07-31
No Actions
Exhibit No. 122 - French
2025-07-31
No Actions
Exhibit No. 007 - DE Commercial Register - Merz Therapeutics GmbH
2025-07-31
No Actions
Exhibit No. 115 - FAMPRIDINE VIATRIS PIL
2025-07-31
No Actions
Exhibit No. 107 - FAMPYRA French Directory
2025-07-31
No Actions
Exhibit No. 124 - Monthly GERS Fampridine Sales
2025-07-31
No Actions
Exhibit No. 009 - FR Commercial Register - Viatris Sante
2025-07-31
No Actions
Exhibit No. 509 - Substituting Generic Product on Ameli
2025-07-31
No Actions
Exhibit No. 127 - Notice Letter 4.07.2025
2025-07-31
No Actions
Exhibit No. 128 - Reply Letter 10.07.2025
2025-07-31
No Actions
Exhibit No. 114 - FAMPRIDINE VIATRIS SmPC
2025-07-31
No Actions
Exhibit No. 110 - FAMPYRA EU Conditional Approval
2025-07-31
No Actions
Exhibit No. 123 - Weekly GERS Fampridine Sales
2025-07-31
No Actions
Exhibit No. 400 - WHO INN List 35
2025-07-31
No Actions
Exhibit No. 132 - FAMPYRA French Co-Payment Notice 04.06.2025
2025-07-31
No Actions
Exhibit No. 300 - EPO T 0799.16 Decision
2025-07-31
No Actions
Exhibit No. 202 - Official Intellectual Property Bulletin 25.13
2025-07-31
No Actions
Exhibit No. 500 - Notice Amendment Generic Distribution- 6.01.2006
2025-07-31
No Actions
Exhibit No. 700 - Proof of payment
2025-07-31
No Actions
Exhibit No. 116 - FAMPRIDINE VIATRIS French Directory
2025-07-31
No Actions
Exhibit No. 211 - French
2025-07-31
No Actions
Exhibit No. 608 - CoA 10x Genomics v NanoString 11.03.2024
2025-07-31
No Actions
Exhibit No. 117 - French
2025-07-31
No Actions
Exhibit No. 211 - French
2025-07-31
No Actions
Exhibit No. 210 - French
2025-07-31
No Actions
Exhibit No. 121 - French
2025-07-31
No Actions
Exhibit No. 009 - FR Commercial Register - Viatris Sante
2025-07-31
No Actions
Exhibit No. 200 - French
2025-07-31
No Actions
Exhibit No. 010 - Viatris Products webpage
2025-07-31
No Actions
Exhibit No. 118 - French
2025-07-31
No Actions
Exhibit No. 404 - Acorda SEC S-1 Form
2025-07-31
No Actions
Exhibit No. 116 - FAMPRIDINE VIATRIS French Directory
2025-07-31
No Actions
Exhibit No. 208 - French
2025-07-31
No Actions
Exhibit No. 205 - EP 536 Patent
2025-07-31
No Actions
Exhibit No. 405 - EMA Guideline MR dosage forms
2025-07-31
No Actions
Exhibit No. 507 - Article L. 138-9
2025-07-31
No Actions
Exhibit No. 601 - CoA Mammut v Orthovox 25.09.2024
2025-07-31
No Actions
Exhibit No. 213 - French
2025-07-31
No Actions
Exhibit No. 113 - EMA Assessment Report
2025-07-31
No Actions
Exhibit No. 121 - French
2025-07-31
No Actions
Exhibit No. 511 - Amendment Order Pharmacists-Health Insurance-5.07.2024
2025-07-31
No Actions
Exhibit No. 403 - Goodman Abstract
2025-07-31
No Actions
Exhibit No. 207 - UPC Opt-Out Extract
2025-07-31
No Actions
Exhibit No. 132 - FAMPYRA French Co-Payment Notice 04.06.2025
2025-07-31
No Actions
Exhibit No. 105 - Kasser et al. 2017
2025-07-31
No Actions
Exhibit No. 206 - French
2025-07-31
No Actions
Exhibit No. 120 - French
2025-07-31
No Actions
Exhibit No. 301 - Federal Patent Court Decision
2025-07-31
No Actions
Exhibit No. 511 - Amendment Order Pharmacists-Health Insurance-5.07.2024
2025-07-31
No Actions
Exhibit No. 100 - Merz FAMPYRA Launch News
2025-07-31
No Actions
Exhibit No. 506 - CFIEC T-201.04 R 22.12.2004
2025-07-31
No Actions
Exhibit No. 013 - Acorda webpage
2025-07-31
No Actions
Exhibit No. 111 - EU Marketing Decisions
2025-07-31
No Actions
Exhibit No. 002 - Merz Businesses webpage
2025-07-31
No Actions
Exhibit No. 130 - FAMPYRA French Public Institution Approval Order 02.06.2025
2025-07-31
No Actions
Exhibit No. 508 - Ceilings for Discounts Decree
2025-07-31
No Actions
Exhibit No. 107 - FAMPYRA French Directory
2025-07-31
No Actions
Exhibit No. 115 - FAMPRIDINE VIATRIS PIL
2025-07-31
No Actions
Letter-for-Service
2025-08-01
No Actions
Notice-to-Accompany-Service-of-Order-for-Measures
2025-08-01
No Actions
Panel-Appointment
2025-08-01
No Actions
Application-For-Measures-Receipt
2025-08-01
No Actions
Formal-checks_Notification-of-positive-outcome
2025-08-01
No Actions
Application-For-Measures-Acknowledgement
2025-08-01
No Actions
Exhibit No. 118 - French
2025-08-01
No Actions
Exhibit No. 505 - CFIEC T-114.06 R 20.07.2006
2025-08-01
No Actions
Exhibit No. 208 - French
2025-08-01
No Actions
Exhibit No. 503 - Toumi et al. External Reference Pricing Simulation
2025-08-01
No Actions
Exhibit No. 125 - Notice Letter 18.06.2025
2025-08-01
No Actions
Exhibit No. 210 - French
2025-08-01
No Actions
Exhibit No. 012 - Viatris France webpage
2025-08-01
No Actions
Exhibit No. 701 - Application - French
2025-08-01
No Actions
Exhibit No. 011 - Viatris Generics webpage
2025-08-01
No Actions
Application for provisional measures
2025-08-01
No Actions
Exhibit No. 130 - FAMPYRA French Public Institution Approval Order 02.06.2025
2025-08-01
No Actions
Exhibit No. 002 - Merz Businesses webpage
2025-08-01
No Actions
Exhibit No. 100 - Merz FAMPYRA Launch News
2025-08-01
No Actions
Exhibit No. 128 - Reply Letter 10.07.2025
2025-08-01
No Actions
Exhibit No. 119 - French
2025-08-01
No Actions
Exhibit No. 601 - CoA Mammut v Orthovox 25.09.2024
2025-08-01
No Actions
Exhibit No. 204 - Merz GmbH and Merz France Short Form Sub-Licence
2025-08-01
No Actions
Exhibit No. 507 - Article L. 138-9
2025-08-01
No Actions
Exhibit No. 008 - FR Commercial Register - Merz Pharma France
2025-08-01
No Actions
Exhibit No. 124 - Monthly GERS Fampridine Sales
2025-08-01
No Actions
Exhibit No. 200 - French
2025-08-01
No Actions
Exhibit No. 112 - FAMPYRA EU Definitive Approval
2025-08-01
No Actions
Exhibit No. 210 - French
2025-08-01
No Actions
Exhibit No. 118 - French
2025-08-01
No Actions
Exhibit No. 700 - Proof of payment
2025-08-01
No Actions
Exhibit No. 301 - Federal Patent Court Decision
2025-08-01
No Actions
Exhibit No. 511 - Amendment Order Pharmacists-Health Insurance-5.07.2024
2025-08-01
No Actions
Exhibit No. 104 - Lublin - Reingold 1996
2025-08-01
No Actions
Application for provisional measures
2025-08-01
No Actions
Exhibit No. 508 - Ceilings for Discounts Decree
2025-08-01
No Actions
Exhibit No. 115 - FAMPRIDINE VIATRIS PIL
2025-08-01
No Actions
Exhibit No. 103 - Lucchinetti et al. 2000
2025-08-01
No Actions
Exhibit No. 500 - Notice Amendment Generic Distribution- 6.01.2006
2025-08-01
No Actions
Exhibit No. 131 - FAMPYRA French Price Notice 04.06.2025
2025-08-01
No Actions
Exhibit No. 109 - FAMPYRA EPAR Summary
2025-08-01
No Actions
Exhibit No. 009 - FR Commercial Register - Viatris Sante
2025-08-01
No Actions
Exhibit No. 117 - French
2025-08-01
No Actions
Exhibit No. 510 - Order Pharmacists-Health Insurance- 31.03.2022
2025-08-01
No Actions
Exhibit No. 200 - French
2025-08-01
No Actions
Exhibit No. 606 - LD Munich 10x Genomics v NanoString 19.09.2023
2025-08-01
No Actions
Exhibit No. 405 - EMA Guideline MR dosage forms
2025-08-01
No Actions
Exhibit No. 012 - Viatris France webpage
2025-08-01
No Actions
Exhibit No. 007 - DE Commercial Register - Merz Therapeutics GmbH
2025-08-01
No Actions
Exhibit No. 105 - Kasser et al. 2017
2025-08-01
No Actions
Exhibit No. 209 - French
2025-08-01
No Actions
Exhibit No. 004 - Acorda Bankruptcy Proceedings and Liquidation Plan
2025-08-01
No Actions
Exhibit No. 509 - Substituting Generic Product on Ameli
2025-08-01
No Actions
Exhibit No. 510 - Order Pharmacists-Health Insurance- 31.03.2022
2025-08-01
No Actions
Exhibit No. 501 - 2021 Health Products Agreement
2025-08-01
No Actions
Exhibit No. 114 - FAMPRIDINE VIATRIS SmPC
2025-08-01
No Actions
Exhibit No. 608 - CoA 10x Genomics v NanoString 11.03.2024
2025-08-01
No Actions
Exhibit No. 302 - EPO T 0421.14 Decision
2025-08-01
No Actions
Exhibit No. 504 - LEEM 2021 Economic Extracts
2025-08-01
No Actions
Exhibit No. 209 - French
2025-08-01
No Actions
Exhibit No. 122 - French
2025-08-01
No Actions
Exhibit No. 107 - FAMPYRA French Directory
2025-08-01
No Actions
Exhibit No. 206 - French
2025-08-01
No Actions
Exhibit No. 120 - French
2025-08-01
No Actions
Exhibit No. 013 - Acorda webpage
2025-08-01
No Actions
Exhibit No. 205 - EP 536 Patent
2025-08-01
No Actions
Exhibit No. 126 - Reply Letter 2.07.2025
2025-08-01
No Actions
Exhibit No. 003 - Merz Therapeutics website
2025-08-01
No Actions
Exhibit No. 504 - LEEM 2021 Economic Extracts
2025-08-01
No Actions
Exhibit No. 128 - Reply Letter 10.07.2025
2025-08-01
No Actions
Exhibit No. 113 - EMA Assessment Report
2025-08-01
No Actions
Exhibit No. 117 - French
2025-08-01
No Actions
Exhibit No. 116 - FAMPRIDINE VIATRIS French Directory
2025-08-01
No Actions
Exhibit No. 212 - Acorda and Merz LLC Short Form Assignment
2025-08-01
No Actions
Exhibit No. 131 - FAMPYRA French Price Notice 04.06.2025
2025-08-01
No Actions
Exhibit No. 206 - French
2025-08-01
No Actions
Exhibit No. 509 - Substituting Generic Product on Ameli
2025-08-01
No Actions
Exhibit No. 124 - Monthly GERS Fampridine Sales
2025-08-01
No Actions
Exhibit No. 607 - CoA 10x Genomics v NanoString 26.02.2024
2025-08-01
No Actions
Exhibit No. 009 - FR Commercial Register - Viatris Sante
2025-08-01
No Actions
Exhibit No. 502 - Kanavos et al. External Reference Pricing Implementation
2025-08-01
No Actions
Exhibit No. 120 - French
2025-08-01
No Actions
Exhibit No. 203 - Merz LLC and Merz GmbH Short Form Licence
2025-08-01
No Actions
Exhibit No. 116 - FAMPRIDINE VIATRIS French Directory
2025-08-01
No Actions
Exhibit No. 123 - Weekly GERS Fampridine Sales
2025-08-01
No Actions
Exhibit No. 106 - Larocca 2011
2025-08-01
No Actions
Exhibit No. 119 - French
2025-08-01
No Actions
Exhibit No. 506 - CFIEC T-201.04 R 22.12.2004
2025-08-01
No Actions
Exhibit No. 400 - WHO INN List 35
2025-08-01
No Actions
Exhibit No. 121 - French
2025-08-01
No Actions
Exhibit No. 110 - FAMPYRA EU Conditional Approval
2025-08-01
No Actions
Exhibit No. 202 - Official Intellectual Property Bulletin 25.13
2025-08-01
No Actions
Exhibit No. 122 - French
2025-08-01
No Actions
Exhibit No. 127 - Notice Letter 4.07.2025
2025-08-01
No Actions
Exhibit No. 605 - CoA Sumi Agro v Syngenta 3.03.2025
2025-08-01
No Actions
Exhibit No. 129 - FAMPYRA French Reimbursement Order 02.06.2025
2025-08-01
No Actions
Exhibit No. 512 - Performance-Based Remuneration
2025-08-01
No Actions
Exhibit No. 132 - FAMPYRA French Co-Payment Notice 04.06.2025
2025-08-01
No Actions
Exhibit No. 213 - French
2025-08-01
No Actions
Exhibit No. 508 - Ceilings for Discounts Decree
2025-08-01
No Actions
Exhibit No. 111 - EU Marketing Decisions
2025-08-01
No Actions
Exhibit No. 132 - FAMPYRA French Co-Payment Notice 04.06.2025
2025-08-01
No Actions
Exhibit No. 115 - FAMPRIDINE VIATRIS PIL
2025-08-01
No Actions
Exhibit No. 010 - Viatris Products webpage
2025-08-01
No Actions
Exhibit No. 404 - Acorda SEC S-1 Form
2025-08-01
No Actions
Exhibit No. 402 - Goodman Slideshow
2025-08-01
No Actions
Exhibit No. 301 - Federal Patent Court Decision
2025-08-01
No Actions
Exhibit No. 211 - French
2025-08-01
No Actions
Exhibit No. 005 - US Commercial Register - Merz Pharmaceuticals LLC
2025-08-01
No Actions
Exhibit No. 108 - FAMPYRA SmPC
2025-08-01
No Actions
Exhibit No. 401 - Goodman Poster
2025-08-01
No Actions
Exhibit No. 107 - FAMPYRA French Directory
2025-08-01
No Actions
Exhibit No. 121 - French
2025-08-01
No Actions
Exhibit No. 202 - Official Intellectual Property Bulletin 25.13
2025-08-01
No Actions
Exhibit No. 300 - EPO T 0799.16 Decision
2025-08-01
No Actions
Exhibit No. 208 - French
2025-08-01
No Actions
Exhibit No. 207 - UPC Opt-Out Extract
2025-08-01
No Actions
Exhibit No. 130 - FAMPYRA French Public Institution Approval Order 02.06.2025
2025-08-01
No Actions
Exhibit No. 123 - Weekly GERS Fampridine Sales
2025-08-01
No Actions
Exhibit No. 211 - French
2025-08-01
No Actions
Exhibit No. 403 - Goodman Abstract
2025-08-01
No Actions
Exhibit No. 507 - Article L. 138-9
2025-08-01
No Actions
Exhibit No. 500 - Notice Amendment Generic Distribution- 6.01.2006
2025-08-01
No Actions
Exhibit No. 001 - Merz History webpage
2025-08-01
No Actions
Exhibit No. 201 - French
2025-08-01
No Actions
Exhibit No. 114 - FAMPRIDINE VIATRIS SmPC
2025-08-01
No Actions
Exhibit No. 213 - French
2025-08-01
No Actions
Exhibit No. 600 - LD Dusseldorf Valeo v Magna 31.10.2024
2025-08-01
No Actions
Exhibit No. 512 - Performance-Based Remuneration
2025-08-01
No Actions
Exhibit No. 604 - CoA Biolitec v Light Guide 24.02.2025
2025-08-01
No Actions
Exhibit No. 006 - Merz - Acorda Asset News
2025-08-01
No Actions
Exhibit No. 511 - Amendment Order Pharmacists-Health Insurance-5.07.2024
2025-08-01
No Actions
Exhibit No. 008 - FR Commercial Register - Merz Pharma France
2025-08-01
No Actions
Exhibit No. 007 - DE Commercial Register - Merz Therapeutics GmbH
2025-08-01
No Actions
Exhibit No. 501 - 2021 Health Products Agreement
2025-08-01
No Actions
Exhibit No. 129 - FAMPYRA French Reimbursement Order 02.06.2025
2025-08-01
No Actions
Exhibit No. 201 - French
2025-08-01
No Actions
Exhibit No. 114 - FAMPRIDINE VIATRIS SmPC
2025-08-01
No Actions
Exhibit No. 213 - French
2025-08-01
No Actions
Exhibit No. 202 - Official Intellectual Property Bulletin 25.13
2025-08-01
No Actions
Exhibit No. 127 - Notice Letter 4.07.2025
2025-08-01
No Actions
Exhibit No. 013 - Acorda webpage
2025-08-01
No Actions
Exhibit No. 604 - CoA Biolitec v Light Guide 24.02.2025
2025-08-01
No Actions
Exhibit No. 701 - Application - French
2025-08-01
No Actions
Exhibit No. 012 - Viatris France webpage
2025-08-01
No Actions
Exhibit No. 123 - Weekly GERS Fampridine Sales
2025-08-01
No Actions
Exhibit No. 104 - Lublin - Reingold 1996
2025-08-01
No Actions
Exhibit No. 507 - Article L. 138-9
2025-08-01
No Actions
Exhibit No. 607 - CoA 10x Genomics v NanoString 26.02.2024
2025-08-01
No Actions
Exhibit No. 502 - Kanavos et al. External Reference Pricing Implementation
2025-08-01
No Actions
Exhibit No. 107 - FAMPYRA French Directory
2025-08-01
No Actions
Exhibit No. 500 - Notice Amendment Generic Distribution- 6.01.2006
2025-08-01
No Actions
Exhibit No. 301 - Federal Patent Court Decision
2025-08-01
No Actions
Exhibit No. 128 - Reply Letter 10.07.2025
2025-08-01
No Actions
Exhibit No. 401 - Goodman Poster
2025-08-01
No Actions
Exhibit No. 126 - Reply Letter 2.07.2025
2025-08-01
No Actions
Exhibit No. 404 - Acorda SEC S-1 Form
2025-08-01
No Actions
Exhibit No. 501 - 2021 Health Products Agreement
2025-08-01
No Actions
Exhibit No. 122 - French
2025-08-01
No Actions
Exhibit No. 503 - Toumi et al. External Reference Pricing Simulation
2025-08-01
No Actions
Exhibit No. 512 - Performance-Based Remuneration
2025-08-01
No Actions
Exhibit No. 128 - Reply Letter 10.07.2025
2025-08-01
No Actions
Exhibit No. 208 - French
2025-08-01
No Actions
Exhibit No. 510 - Order Pharmacists-Health Insurance- 31.03.2022
2025-08-01
No Actions
Exhibit No. 700 - Proof of payment
2025-08-01
No Actions
Exhibit No. 211 - French
2025-08-01
No Actions
Exhibit No. 106 - Larocca 2011
2025-08-01
No Actions
Exhibit No. 003 - Merz Therapeutics website
2025-08-01
No Actions
Exhibit No. 117 - French
2025-08-01
No Actions
Exhibit No. 105 - Kasser et al. 2017
2025-08-01
No Actions
Exhibit No. 122 - French
2025-08-01
No Actions
Exhibit No. 004 - Acorda Bankruptcy Proceedings and Liquidation Plan
2025-08-01
No Actions
Exhibit No. 507 - Article L. 138-9
2025-08-01
No Actions
Exhibit No. 110 - FAMPYRA EU Conditional Approval
2025-08-01
No Actions
Exhibit No. 012 - Viatris France webpage
2025-08-01
No Actions
Exhibit No. 300 - EPO T 0799.16 Decision
2025-08-01
No Actions
Exhibit No. 211 - French
2025-08-01
No Actions
Exhibit No. 512 - Performance-Based Remuneration
2025-08-01
No Actions
Exhibit No. 405 - EMA Guideline MR dosage forms
2025-08-01
No Actions
Exhibit No. 103 - Lucchinetti et al. 2000
2025-08-01
No Actions
Exhibit No. 118 - French
2025-08-01
No Actions
Exhibit No. 207 - UPC Opt-Out Extract
2025-08-01
No Actions
Exhibit No. 118 - French
2025-08-01
No Actions
Exhibit No. 131 - FAMPYRA French Price Notice 04.06.2025
2025-08-01
No Actions
Exhibit No. 117 - French
2025-08-01
No Actions
Exhibit No. 121 - French
2025-08-01
No Actions
Exhibit No. 508 - Ceilings for Discounts Decree
2025-08-01
No Actions
Exhibit No. 204 - Merz GmbH and Merz France Short Form Sub-Licence
2025-08-01
No Actions
Exhibit No. 205 - EP 536 Patent
2025-08-01
No Actions
Exhibit No. 007 - DE Commercial Register - Merz Therapeutics GmbH
2025-08-01
No Actions
Exhibit No. 119 - French
2025-08-01
No Actions
Exhibit No. 124 - Monthly GERS Fampridine Sales
2025-08-01
No Actions
Exhibit No. 200 - French
2025-08-01
No Actions
Exhibit No. 108 - FAMPYRA SmPC
2025-08-01
No Actions
Exhibit No. 206 - French
2025-08-01
No Actions
Exhibit No. 504 - LEEM 2021 Economic Extracts
2025-08-01
No Actions
Exhibit No. 302 - EPO T 0421.14 Decision
2025-08-01
No Actions
Exhibit No. 006 - Merz - Acorda Asset News
2025-08-01
No Actions
Exhibit No. 403 - Goodman Abstract
2025-08-01
No Actions
Exhibit No. 120 - French
2025-08-01
No Actions
Exhibit No. 605 - CoA Sumi Agro v Syngenta 3.03.2025
2025-08-01
No Actions
Exhibit No. 111 - EU Marketing Decisions
2025-08-01
No Actions
Exhibit No. 009 - FR Commercial Register - Viatris Sante
2025-08-01
No Actions
Exhibit No. 007 - DE Commercial Register - Merz Therapeutics GmbH
2025-08-01
No Actions
Exhibit No. 511 - Amendment Order Pharmacists-Health Insurance-5.07.2024
2025-08-01
No Actions
Exhibit No. 010 - Viatris Products webpage
2025-08-01
No Actions
Exhibit No. 124 - Monthly GERS Fampridine Sales
2025-08-01
No Actions
Exhibit No. 119 - French
2025-08-01
No Actions
Exhibit No. 402 - Goodman Slideshow
2025-08-01
No Actions
Exhibit No. 509 - Substituting Generic Product on Ameli
2025-08-01
No Actions
Exhibit No. 115 - FAMPRIDINE VIATRIS PIL
2025-08-01
No Actions
Exhibit No. 115 - FAMPRIDINE VIATRIS PIL
2025-08-01
No Actions
Exhibit No. 509 - Substituting Generic Product on Ameli
2025-08-01
No Actions
Exhibit No. 506 - CFIEC T-201.04 R 22.12.2004
2025-08-01
No Actions
Exhibit No. 209 - French
2025-08-01
No Actions
Exhibit No. 212 - Acorda and Merz LLC Short Form Assignment
2025-08-01
No Actions
Exhibit No. 201 - French
2025-08-01
No Actions
Exhibit No. 121 - French
2025-08-01
No Actions
Exhibit No. 202 - Official Intellectual Property Bulletin 25.13
2025-08-01
No Actions
Exhibit No. 131 - FAMPYRA French Price Notice 04.06.2025
2025-08-01
No Actions
Exhibit No. 505 - CFIEC T-114.06 R 20.07.2006
2025-08-01
No Actions
Exhibit No. 130 - FAMPYRA French Public Institution Approval Order 02.06.2025
2025-08-01
No Actions
Exhibit No. 210 - French
2025-08-01
No Actions
Exhibit No. 203 - Merz LLC and Merz GmbH Short Form Licence
2025-08-01
No Actions
Exhibit No. 601 - CoA Mammut v Orthovox 25.09.2024
2025-08-01
No Actions
Exhibit No. 100 - Merz FAMPYRA Launch News
2025-08-01
No Actions
Exhibit No. 608 - CoA 10x Genomics v NanoString 11.03.2024
2025-08-01
No Actions
Exhibit No. 113 - EMA Assessment Report
2025-08-01
No Actions
Exhibit No. 504 - LEEM 2021 Economic Extracts
2025-08-01
No Actions
Application for provisional measures
2025-08-01
No Actions
Exhibit No. 109 - FAMPYRA EPAR Summary
2025-08-01
No Actions
Exhibit No. 116 - FAMPRIDINE VIATRIS French Directory
2025-08-01
No Actions
Exhibit No. 011 - Viatris Generics webpage
2025-08-01
No Actions
Exhibit No. 116 - FAMPRIDINE VIATRIS French Directory
2025-08-01
No Actions
Exhibit No. 606 - LD Munich 10x Genomics v NanoString 19.09.2023
2025-08-01
No Actions
Exhibit No. 501 - 2021 Health Products Agreement
2025-08-01
No Actions
Exhibit No. 120 - French
2025-08-01
No Actions
Exhibit No. 132 - FAMPYRA French Co-Payment Notice 04.06.2025
2025-08-01
No Actions
Exhibit No. 208 - French
2025-08-01
No Actions
Exhibit No. 209 - French
2025-08-01
No Actions
Exhibit No. 508 - Ceilings for Discounts Decree
2025-08-01
No Actions
Exhibit No. 210 - French
2025-08-01
No Actions
Exhibit No. 001 - Merz History webpage
2025-08-01
No Actions
Exhibit No. 301 - Federal Patent Court Decision
2025-08-01
No Actions
Exhibit No. 129 - FAMPYRA French Reimbursement Order 02.06.2025
2025-08-01
No Actions
Exhibit No. 123 - Weekly GERS Fampridine Sales
2025-08-01
No Actions
Exhibit No. 206 - French
2025-08-01
No Actions
Exhibit No. 114 - FAMPRIDINE VIATRIS SmPC
2025-08-01
No Actions
Exhibit No. 002 - Merz Businesses webpage
2025-08-01
No Actions
Exhibit No. 510 - Order Pharmacists-Health Insurance- 31.03.2022
2025-08-01
No Actions
Exhibit No. 129 - FAMPYRA French Reimbursement Order 02.06.2025
2025-08-01
No Actions
Exhibit No. 200 - French
2025-08-01
No Actions
Exhibit No. 500 - Notice Amendment Generic Distribution- 6.01.2006
2025-08-01
No Actions
Exhibit No. 600 - LD Dusseldorf Valeo v Magna 31.10.2024
2025-08-01
No Actions
Exhibit No. 009 - FR Commercial Register - Viatris Sante
2025-08-01
No Actions
Exhibit No. 511 - Amendment Order Pharmacists-Health Insurance-5.07.2024
2025-08-01
No Actions
Exhibit No. 201 - French
2025-08-01
No Actions
Exhibit No. 213 - French
2025-08-01
No Actions
Exhibit No. 008 - FR Commercial Register - Merz Pharma France
2025-08-01
No Actions
Exhibit No. 132 - FAMPYRA French Co-Payment Notice 04.06.2025
2025-08-01
No Actions
Exhibit No. 107 - FAMPYRA French Directory
2025-08-01
No Actions
Exhibit No. 400 - WHO INN List 35
2025-08-01
No Actions
Exhibit No. 008 - FR Commercial Register - Merz Pharma France
2025-08-01
No Actions
Exhibit No. 130 - FAMPYRA French Public Institution Approval Order 02.06.2025
2025-08-01
No Actions
Exhibit No. 112 - FAMPYRA EU Definitive Approval
2025-08-01
No Actions
Exhibit No. 005 - US Commercial Register - Merz Pharmaceuticals LLC
2025-08-01
No Actions
Exhibit No. 125 - Notice Letter 18.06.2025
2025-08-01
No Actions
Panel-Appointment
2025-08-05
No Actions
Notification Of Service
2025-08-06
No Actions
digital tracking La Poste - Service receipt
2025-08-06
No Actions
Acknowledgement of access to case
2025-08-07
No Actions
Panel-Appointment
2025-08-14
No Actions
Hearing-Dates
2025-08-18
No Actions
procedural order timetable and summon OH
2025-08-18
Summon-Oral-Hearing
2025-09-11
No Actions
Order 18-08-2025 summon the oral hearing
2025-09-11
PJ032 Decision de la Chambre de recours de lOEB 29 mai 2001 T 009198 GB
2025-09-15
No Actions
PC050 Extract from the National Institutes of Health website FDA Drug Review and Approval GB
2025-09-15
No Actions
PC083 Barus et al 2022 FR
2025-09-15
No Actions
PJ078 Case law of the boards of Appeal ID108 GB
2025-09-15
No Actions
PC081 ICHT topic 9 guideline on statistical principles for clinical trials September 1998 GB
2025-09-15
No Actions
PC071 Germany ratiopharm 20240304 Revocation of patent EP 536 DE
2025-09-15
No Actions
PJ058 TJ Paris Refere 17 juin 2021 RG 2153849 Cabazitaxel Sanofi c Ever Pharma FR
2025-09-15
No Actions
PC084 AFSEP press release of 28 May 2025 FR
2025-09-15
No Actions
PC137 They are looking for a superpill for Alzheimers Technologies News Standard 2013 BG
2025-09-15
No Actions
PJ086 Court of Appeal 10x Genomics Harvard v NanoString UPC CoA 3352023 GB
2025-09-15
No Actions
PC098 Le Progres Article Patients deprived of a medication due to a change of packaging 26 June 2025 FR
2025-09-15
No Actions
PC097 Screenshots of patients testimonies online 1 2 FR
2025-09-15
No Actions
PC102 Clinical studies in 20 questions Atelier Presse Clinical trials LEEM 19 May 2011 FR
2025-09-15
No Actions
PJ067 LD Munich 15 November 2024 UPC CFI 152023 GB
2025-09-15
No Actions
PJ082 Phosphodiesterase NL Appeal court of the Hague Appel 27082019 NL
2025-09-15
No Actions
PC046 US 8 354 437 GB
2025-09-15
No Actions
PJ024 JUB Cour dAppel 26 fevrier 2024 NanoString c 10x Genomics UPCCoA3352023 GB
2025-09-15
No Actions
PC058 Federal Court of Appeal of Canada 8 August 2022 Acorda Therapeutics v Pharmascience Taro Pharmaceuticals A 145 20
2025-09-15
No Actions
PC074 USA 20170425 Delaware District Court 25 avril 2017 Acorda v Teva Roxane Mylan 14 882 GB
2025-09-15
No Actions
PJ008 TJ Paris 29 septembre 2021 RG 21 55930 FR
2025-09-15
No Actions
PC142 Kostadinova and Danchev 2019 GB
2025-09-15
No Actions
PC129 Iqvia About us GB
2025-09-15
No Actions
PC115 Sheeber et al 1996 Data analytic techniques for treatment outcome studies with pretest posttest measurements an ex
2025-09-15
No Actions
PC061 L echelle EDSS Expanded Disability Status Scale FR
2025-09-15
No Actions
PC005 EP 2 377 536 B2 GB
2025-09-15
No Actions
PJ054 Cour dappel de Paris 14 fevrier 1991 Newtec International c Sfeima PIBD n504 IIII432 FR
2025-09-15
No Actions
PJ055 TGI Paris 22 septembre 2017 1407707 FR
2025-09-15
No Actions
PC024 Bever et al 1994 Juin Neurology 44 1054 1059 GB
2025-09-15
No Actions
PJ049 Decision de la Chambre de recours 3502 de lOEB 29 octobre 2019 T 33515 FR
2025-09-15
No Actions
PC062 Cohen Postgraduate Medicine Septembre 1999 GB
2025-09-15
No Actions
PC031 SEC Overview GB
2025-09-15
No Actions
PC014 Journal de la societe statistique de Paris 1956 FR
2025-09-15
No Actions
PJ072 Hamburg Local Division 3 June 2024 UPCCFI1512024 GB
2025-09-15
No Actions
PC011 Edwards and Aronson The Lancet Vol 356 October 7 2000 GB
2025-09-15
No Actions
PC101 Report by Dr Christian Wolf dated 2 September 2022 GB
2025-09-15
No Actions
PC067 EMEA Points to consider on the choice of non interiority margin 2004 GB
2025-09-15
No Actions
PC016 Piece composite Synthese Wikipiedia sur l ecart type et la valeur P FR
2025-09-15
No Actions
PJ083 Fingolimod DE OLG Dusseldorf Appel 03082023 DE
2025-09-15
No Actions
PC048 US 8 663 685 GB
2025-09-15
No Actions
PC140 OLG Munchen Acorda Therapeutics v Ratiopharm 6 October 2022 6 U 3044 22 DE
2025-09-15
No Actions
PC089 RNB EP 536 FR
2025-09-15
No Actions
PC128 Adverse exhibit No 503 Toumi et al External Reference Pricing Simulation GB
2025-09-15
No Actions
PC051 Kaufman al 2000 The significant change for the Timed 25 Foot Walk in the Multiple Sclerosis Functional Composite M
2025-09-15
No Actions
PJ076 UPC Court of Appeal 25 September 2024 UPCCoA1822024 GB
2025-09-15
No Actions
Objection Viatris Sante 15092025 APP 339802025 compressed signed
2025-09-15
No Actions
PJ068 Court of Appeal Biolitec v Light Guide Optics SIA Lightguide 24 February 2025 UPCCoA5402024 GB
2025-09-15
No Actions
PJ036 TJ Paris 7 juin 2021 RG 2153474 Sanofi c Accord cabazitaxel FR
2025-09-15
No Actions
PC066 EMEA 27 July 2000 Points to consider on switching betweend superiority and non inferiority GB
2025-09-15
No Actions
PC028 van Diemen et al 1992 August GB
2025-09-15
No Actions
PJ062 Directive 200448CE GB
2025-09-15
No Actions
PC078 Info Sheet FAMPYRA 10mg sustained release tablet FR
2025-09-15
No Actions
PC020 Merz acquires Fampyra GB
2025-09-15
No Actions
PJ034 Cour dappel de Paris 18 Decembre 2018 RG n 1710112 FR
2025-09-15
No Actions
PC122 Application for provisional measures GB
2025-09-15
No Actions
PC086 Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects GB
2025-09-15
No Actions
PC056 Polman Arch Neur Vol 51 novembre 1994 GB
2025-09-15
No Actions
PC148 The fixing of the price and reimboursement rate sante gouv FR
2025-09-15
No Actions
PJ043 BASF C25899 GB
2025-09-15
No Actions
PC113 Vickers 2003 Hor many repeated measures in repeates measures designs Statistical issues for comparative Trials BMC
2025-09-15
No Actions
PC055 Sheiner Clin Pharmacol Ther Volume 46 Number 1 Juillet 1989 GB
2025-09-15
No Actions
PC133 SmPC Pymadin BG
2025-09-15
No Actions
PC105 DTX 584 GB
2025-09-15
No Actions
PC052 Schwid et al 2002 April GB
2025-09-15
No Actions
PC130 4 aminopiridin Spinal Cord Injury Forum RU compressed
2025-09-15
No Actions
PJ084 DMF BE Cour dAppel de Bruxelles Appel 30012023 NL
2025-09-15
No Actions
PC013 Ting N Introduction and New Drug Development Process In Ting N editor Dose Finding in Drug Development Springer Ne
2025-09-15
No Actions
PJ080 Munich Local Division 21 May 2024 UPCCFI432023 DE
2025-09-15
No Actions
PC090 RNB CCP 033 FR
2025-09-15
No Actions
PC138 Website of the faculty of medicine in Sofia BG
2025-09-15
No Actions
PJ035 CA Paris 29 octobre 2019 ETYPHARM c MERCK RG n1803876 FR
2025-09-15
No Actions
PC082 Extrait de la Base de Donnees Publique des Medicaments Fampridine Viatris 10 mg FR
2025-09-15
No Actions
PJ012 Munich Local Division 27 August 2024 UPCCFI2012024 GB
2025-09-15
No Actions
PC138 Website of the faculty of medicine in Sofia BG
2025-09-15
No Actions
PC136 Russian State Archive of Scientific and Technical Documentation RU
2025-09-15
No Actions
PC139 UPSTO Trademark Status Document Retrieval Pymadin Sopharma GB
2025-09-15
No Actions
PC080 website of the Foundation for Research into Multiple Sclerosis FR
2025-09-15
No Actions
PJ048 Decision de la Chambre de recours de lOEB 10 novembre 1988 T038187 GB
2025-09-15
No Actions
PJ070 Dusseldorf Local Division 9 April 2024 UPCCFI4522023 DE
2025-09-15
No Actions
PC075 Federal Court of Canada 15 May 2020 Acorda v Pharmascience and Taro T 1416 18 and T 220 19 GB
2025-09-15
No Actions
PC079 Notice on the prices of Fampridine pharmaceutical specialities FR
2025-09-15
No Actions
PC107 Petkau 1998 Seminars in Neurology Vol 18 3 GB
2025-09-15
No Actions
PC063 Form 10 K Wikipedia Presentation GB
2025-09-15
No Actions
PJ022 Decision de la Chambre de recours 332 de lOEB 2 juin 2003 T 30899 GB
2025-09-15
No Actions
PJ011 TJ Paris 27 juillet 2022 RG n 22 54367 FR
2025-09-15
No Actions
PC089 RNB EP 536 FR
2025-09-15
No Actions
PC068 Decision of the EPO EP 536 GB compressed
2025-09-15
No Actions
PJ087 Regulation n 469 2009 GB
2025-09-15
No Actions
PC140 OLG Munchen Acorda Therapeutics v Ratiopharm 6 October 2022 6 U 3044 22 DE
2025-09-15
No Actions
PJ082 Phosphodiesterase NL Appeal court of the Hague Appel 27082019 NL
2025-09-15
No Actions
PJ030 Decision de la Chambre de recours de lOEB 6 octobre 2004 T 91801 GB
2025-09-15
No Actions
PC078 Info Sheet FAMPYRA 10mg sustained release tablet FR
2025-09-15
No Actions
PC012 Pirmohamed et al BMJ VOLUME 316 25 APRIL 1998 GB
2025-09-15
No Actions
PJ006 CJEU 16 July 2024 Genmab v Hungarian IP Office SPC C 181 24 GB
2025-09-15
No Actions
PC015 Marien et Beaud Guide pratique pour l utilisation de la statistique en recherche 2003 FR
2025-09-15
No Actions
PJ023 Decision de la chambre de recours 332 de l OEB 26 fevrier 2004 T 92600 GB
2025-09-15
No Actions
PC008 BOPI 20 novembre 2015 n 1547 pp 235 237 et 258 FR
2025-09-15
No Actions
PJ025 JUB Division centrale de Munich 16 juillet 2024 Sanofi c Amgen UPCCFI 12023 GB
2025-09-15
No Actions
PC017 Verhagen et al Australian Journal of Physiotherapy 2004 Vol 50 GB
2025-09-15
No Actions
PC087 CCNE Opinion 79 Transposition into French law of the European Directive on clinical trials of medicinal products F
2025-09-15
No Actions
PJ040 Abraxis C 443 17 21 mars 2019 GB
2025-09-15
No Actions
PC045 Declaration of Dr Ron Cohen GB
2025-09-15
No Actions
PC001 Extrait Kbis VIATRIS SANTE FR
2025-09-15
No Actions
PC004 Fampyra SmPC GB
2025-09-15
No Actions
PC076 Kehl Responder Identification in Clinical Trials with Censored Data 2003 GB
2025-09-15
No Actions
PJ075 Guidelines for Examination in the European Patent Office GVII4GB
2025-09-15
No Actions
PC047 US 8 440 703 GB
2025-09-15
No Actions
PC007 Decision et requete de delivrance du CCP n 13 C0033 FR
2025-09-15
No Actions
PC009 Griffin et al The textbook of Pharmaceutical Medicine 1993 Pages 221 222 GB compressed
2025-09-15
No Actions
PC007 Decision et requete de delivrance du CCP n 13 C0033 FR
2025-09-15
No Actions
PC077 Accession of Bulgaria GB
2025-09-15
No Actions
PJ085 DMF NL court of the Hague 1ere instance 22012025 NL
2025-09-15
No Actions
PC025 Bever 1994 The American Neurological Association 1994 volume 23 page 118 S121 GB
2025-09-15
No Actions
PC036 ACTRIMS ECTRIMS Final Program GB compressed
2025-09-15
No Actions
PJ073 EPO BoA 10 July 2025 Eisai v STADA lenvatinib T 193423 GB
2025-09-15
No Actions
PC092 Juillet 1986 Comment determiner la posologie optimale d un medicament FR
2025-09-15
No Actions
PC061 L echelle EDSS Expanded Disability Status Scale FR
2025-09-15
No Actions
PC021 List of documents cited in the oppositions GB
2025-09-15
No Actions
PC134 Patient Leaflet Pymadin BG
2025-09-15
No Actions
PC134 Patient Leaflet Pymadin BG
2025-09-15
No Actions
PC087 CCNE Opinion 79 Transposition into French law of the European Directive on clinical trials of medicinal products F
2025-09-15
No Actions
PC094 Hayes et al 2003 Pharmacokinetic studies of single and multiple oral doses of fampridine Vol 26 n4 pp 185 192 GB
2025-09-15
No Actions
PC088 CHMP 1999 Clinical investigation of medicinal products in the treatment of Parkinson s disease CPMP note for guida
2025-09-15
No Actions
PC072 Germany Teva 20230711 Revocation of patent EP 548 DE
2025-09-15
No Actions
PC002 RCP Fampridine Viatris LP 10mg FR
2025-09-15
No Actions
PJ081 DMF DE OLG Dusseldorf Appel 23022023 DE
2025-09-15
No Actions
PJ013 TJ Paris 18 juin 2025 RG n 23 02356 FR
2025-09-15
No Actions
PC003 Commission Implementing Decision of 27 September 2024 C20246926 GB
2025-09-15
No Actions
PC120 Acorda v Alkem Trial Transcript Volume A GB
2025-09-15
No Actions
PJ019 CA Paris 19 janvier 2021 RG 18 21115 FR
2025-09-15
No Actions
PC070 Germany ratiopharm 20221206 Admissibility of the EP 536 invalidity claim DE
2025-09-15
No Actions
PC083 Barus et al 2022 FR
2025-09-15
No Actions
PC098 Le Progres Article Patients deprived of a medication due to a change of packaging 26 June 2025 FR
2025-09-15
No Actions
PJ077 Bonnes pratiques de distribution ANSM Bulletin officiel n20149bis FR
2025-09-15
No Actions
PC133 SmPC Pymadin BG
2025-09-15
No Actions
PC040 NINDS Fatigue Severity Scale FSS GB
2025-09-15
No Actions
PC044 US 8 007 826 GB
2025-09-15
No Actions
PC014 Journal de la societe statistique de Paris 1956 FR
2025-09-15
No Actions
PC135 Communication between the CEPS and VIATRIS FR
2025-09-15
No Actions
PC091 Dose ranging study Wikipedia GB
2025-09-15
No Actions
PC103 Stefoski et al 1991 4 Aminopyridine in multiple sclerosis Prolonged administration Neurology 1991 GB
2025-09-15
No Actions
PC002 RCP Fampridine Viatris LP 10mg FR
2025-09-15
No Actions
PJ065 CJEU 28 July 2011 Synthon c Mertz memantine C19509 GB
2025-09-15
No Actions
PC041 National Multiple Sclerosis Society Timed 25 Foot Walk T25 FW GB
2025-09-15
No Actions
PJ052 TGI Paris 6 juin 2019 RG n1606916 FR
2025-09-15
No Actions
PC145 Letter from VIATRIS to MERZ of 10 July 2025 FR
2025-09-15
No Actions
PC023 Davis et al 1990 The American Neurological Association 1990 pages 186 192 GB
2025-09-15
No Actions
PC079 Notice on the prices of Fampridine pharmaceutical specialities FR
2025-09-15
No Actions
PC026 Schwid et al 1997 The American Academy of Neurology volume 48 pages 817 821 GB
2025-09-15
No Actions
PC015 Marien et Beaud Guide pratique pour l utilisation de la statistique en recherche 2003 FR
2025-09-15
No Actions
PJ061 Neurim Mylan High Court of Justice 3 juin 2020 EWHC 1362 GB
2025-09-15
No Actions
PC111 Schulz et al 2003 The efficacy of quetiapine vs haloperidol and placebo a meta analytic study of efficacy Schizopp
2025-09-15
No Actions
PC095 CPMP Points to consider multiplicity issues clinical trials 2002 GB
2025-09-15
No Actions
PC008 BOPI 20 novembre 2015 n 1547 pp 235 237 et 258 FR
2025-09-15
No Actions
PC064 USA 20181010 Court of appeal 10 septembre 2018 Acorda v Roxane et al 2017 2078 et 2017 2134 GB
2025-09-15
No Actions
PC148 The fixing of the price and reimboursement rate sante gouv FR
2025-09-15
No Actions
PJ046 Decision de la Chambre de recours de lOEB 20 septembre 2011 T197909 GB
2025-09-15
No Actions
PC006 Demande de CCP sur la base du brevet EP 2 377 536 FR
2025-09-15
No Actions
PC106 Leber et Davis 1998 Threats to the validity of clinical trials employing enrichment strategies for sample selectio
2025-09-15
No Actions
PJ020-Decision de la Chambre de recours 332 de lOEB 13 juillet 2004 T 393 01 GB
2025-09-15
No Actions
PC035 List of references IDS GB
2025-09-15
No Actions
PC109 Lewis 2002 Statistics in Medicine Vol 21 pages 2931 2938 GB
2025-09-15
No Actions
PC071 Germany ratiopharm 20240304 Revocation of patent EP 536 DE
2025-09-15
No Actions
PC033 Acorda Therapeutics Form S1 2003 GB
2025-09-15
No Actions
PC030 Goodman Abstract Poster GB
2025-09-15
No Actions
PJ004 Regulation No 1768 92 GB
2025-09-15
No Actions
PC112 Uryniak et al 2011 Responder Analyses A PhRMA Position Paper Statistics in Biopharmaceutical Research Vol 3 N3 GB
2025-09-15
No Actions
PC110 Temple 1994 Commun Stat Theory Meth Vol 23 pages 449 521 GB
2025-09-15
No Actions
PC084 AFSEP press release of 28 May 2025 FR
2025-09-15
No Actions
PJ069 Dusseldorf Local Division Valeo v Magna 31102024 UPC CFI 3682024 GB
2025-09-15
No Actions
PJ071 Dusseldorf Local Division 30 April 2024 UPCCFI4632023 GB
2025-09-15
No Actions
PC145 Letter from VIATRIS to MERZ of 10 July 2025 FR
2025-09-15
No Actions
PC029 Shargel 1999 Applied Biopharmaceutics and Pharmacokinetics Chapter 7 Extraits pages 169 178 179 GB compressed
2025-09-15
No Actions
PJ026 TGI Paris 7 mai 2010 Hexal c Boehringer RG 0812537 FR
2025-09-15
No Actions
PJ045 Decision de la Chambre de recours de lOEB 1er avril 2009 T 140906 GB
2025-09-15
No Actions
PC069 Board of Appeal of the European Patent Office 4 September 2019 T 0799 16 GB
2025-09-15
No Actions
PJ017 CA Paris 14 novembre 2017 RG n 1502576 FR
2025-09-15
No Actions
PJ005 Accord cadre LEEM CEPS 5 mars 2021 FR
2025-09-15
No Actions
PC034 List of documents requested US 11 102 559 GB
2025-09-15
No Actions
PJ027 Jurisprudences francaises essais de routine FR
2025-09-15
No Actions
PC090 RNB CCP 033 FR
2025-09-15
No Actions
PJ016 TJ Paris 28 mars 2024 RG 2208612 FR
2025-09-15
No Actions
PJ021 Decision de la Chambre de recours 352 de lOEB 22 octobre 1993 T 25392 GB
2025-09-15
No Actions
PC010 ICH Topic E 8 General Considerations for Clinical Trials 17 july 1997 GB
2025-09-15
No Actions
PC097 Screenshots of patients testimonies online 1 2 FR
2025-09-15
No Actions
PJ041 CA Paris 14 fevrier 2020 RG 1903820 Sandoz c MSD FR
2025-09-15
No Actions
PC059 Ellen R Girden Anova repeated measures 1992 GB
2025-09-15
No Actions
PJ079 CA Paris 9 juillet 2025 n2407962 FR
2025-09-15
No Actions
PC016 Piece composite Synthese Wikipiedia sur l ecart type et la valeur P FR
2025-09-15
No Actions
PC099 Matusik 2022 Therapy Nutrients 2022 14 4249 GB
2025-09-15
No Actions
PC131 Disaster Protection Plan Burgas Region Republic of Bulgaria 2012 BG
2025-09-15
No Actions
PC018 EP536 Oral Proceedings GB
2025-09-15
No Actions
PJ059 Decision de la Chambre de recours de lOEB 4 octobre 2016 T250612 GB
2025-09-15
No Actions
PJ003 TJ Paris Ordonnance Viatris c Novartis 04 aout 2022 fingolimod RG n 2254655 FR
2025-09-15
No Actions
PC135 Communication between the CEPS and VIATRIS FR
2025-09-15
No Actions
PC130 4 aminopiridin Spinal Cord Injury Forum RU compressed
2025-09-15
No Actions
PC042 Medical Research Council MRC Scale for Muscle Strength GB
2025-09-15
No Actions
PC121 Acorda v Alkem Trial Transcript Volume B GB
2025-09-15
No Actions
PC131 Disaster Protection Plan Burgas Region Republic of Bulgaria 2012 BG
2025-09-15
No Actions
PC149 IQVIA Data unredacted version GB
2025-09-15
No Actions
PC038 Goodman Poster Placebo Controlled Double blinded Dose Ranging Study of Fampridine SR in Multiple Sclerosis GB
2025-09-15
No Actions
PC049 CA 2 562 277 GB
2025-09-15
No Actions
PC146 Letter from Viatris to Mez dated 2 July 2025 GB
2025-09-15
No Actions
PC104 4 Aminopyridine induces functional improvement in multiple sclerosis patients a neurophysiological study GB
2025-09-15
No Actions
PC070 Germany ratiopharm 20221206 Admissibility of the EP 536 invalidity claim DE
2025-09-15
No Actions
PC151 Declaration Dawid Sierzant du 15 septembre 2025 et annexes GB
2025-09-15
No Actions
PC037 Supplemental Information Disclosure Statement GB
2025-09-15
No Actions
PC027 EP 0 484 186 B1 GB
2025-09-15
No Actions
PJ038 TJ Paris 20 janvier 2022 RG n 1901997 FR
2025-09-15
No Actions
PJ001-Decision du Conseil constitutionnel n 2002 463 DC du 12 decembre 2002 FR
2025-09-15
No Actions
PC082 Extrait de la Base de Donnees Publique des Medicaments Fampridine Viatris 10 mg FR
2025-09-15
No Actions
PC108 Weiner 1998 Can J Neurol Sci Vol 25 pages 93101 GB
2025-09-15
No Actions
PJ051 TGI Rennes 2 septembre 2002 RG n9803029 FR
2025-09-15
No Actions
PJ084 DMF BE Cour dAppel de Bruxelles Appel 30012023 NL
2025-09-15
No Actions
PJ018 TJ Paris 20 juillet 2023 RG n 21 10327 FR
2025-09-15
No Actions
PJ005 Accord cadre LEEM CEPS 5 mars 2021 FR
2025-09-15
No Actions
PJ044 Decision de la Chambre de recours de lOEB du 28 janvier 2019 T 023715 GB
2025-09-15
No Actions
PJ010 Guidelines for examination of the EPO GIV1 GB
2025-09-15
No Actions
PC006 Demande de CCP sur la base du brevet EP 2 377 536 FR
2025-09-15
No Actions
PJ050 Decision de la Chambre de recours 3306 de lOEB 30 mai 2000 T 16596 FR
2025-09-15
No Actions
PJ028 Case law of the Boards of Appeal of the EPO ID71 Reasonable expectation of success GB
2025-09-15
No Actions
PJ081 DMF DE OLG Dusseldorf Appel 23022023 DE
2025-09-15
No Actions
PJ077 Bonnes pratiques de distribution ANSM Bulletin officiel n20149bis FR
2025-09-15
No Actions
PC085 Nuremberg Code GB
2025-09-15
No Actions
PC053 Excerpt from the FDA website Drug Evaluation Process GB
2025-09-15
No Actions
PC141 Sartori et al 1994 GB
2025-09-15
No Actions
PC096 Kehl Responder Identification in Clinical Trials juin 2002 GB
2025-09-15
No Actions
PJ002 CA Paris 14 fevrier 2020 RG 1906114 FR
2025-09-15
No Actions
PJ037 TJ Paris 6 septembre 2024 RG n2106416 FR
2025-09-15
No Actions
PJ047 TJ Paris 22 juin 2023 RG n2002792 FR
2025-09-15
No Actions
PJ031 Decision de la Chambre de recours de lOEB 5 octobre 2000 T 33397 GB
2025-09-15
No Actions
PC022 Sherratt et al 1980 Nature volume 283 5745 pages 570 572 GB
2025-09-15
No Actions
PC097 Screenshots of patients testimonies online 2 2 FR
2025-09-15
No Actions
PJ053 Cour de Cassation 20 novembre 2012 Pourvoi n 1118440 FR
2025-09-15
No Actions
PC132 Free State Gazette edition 33 of 2IV 2002 Unofficial section RU
2025-09-15
No Actions
PJ014 UPC Court of Appeal 13 August 2025 UPCCoA4462025 GB
2025-09-15
No Actions
PJ029 Decision de la Chambre de Recours de lOEB 14 fevrier 1989 T 24988 GB
2025-09-15
No Actions
PC060 O Brien Journal of Hypertension 2003 GB
2025-09-15
No Actions
PJ042 GSK C21013 14 nov 2013 GB
2025-09-15
No Actions
PJ039 Case law of the Boards of Appeal of the EPO I D 74 Try and see solution GB
2025-09-15
No Actions
PC116 SAS Library 1997 Repeated measures ANOVA using SAS PROC GLM GB
2025-09-15
No Actions
PC132 Free State Gazette edition 33 of 2IV 2002 Unofficial section RU
2025-09-15
No Actions
PJ033 Decision de la Chambre de recours de lOEB 25 juillet 2017 T 025915 GB
2025-09-15
No Actions
PJ009 CA Paris 25 mai 2022 RG 21 18398 FR
2025-09-15
No Actions
PC100 EP1732548B9 GB
2025-09-15
No Actions
PC054 Norleans 2001 Statistical Methods for Clinical Trials GB compressed
2025-09-15
No Actions
PC073 USA 20170331 Delaware District Court 31 mars 2017 Acorda v Roxane 14 882 LPS GB
2025-09-15
No Actions
PC136 Russian State Archive of Scientific and Technical Documentation RU
2025-09-15
No Actions
PJ063 Cass Com 10 fevrier 2015 n1320150 FR
2025-09-15
No Actions
PC117 Alhainen et al 1991 Discrimination of tetrahydroaminoacridine responders by a single dose pharmaco EEG in patients
2025-09-15
No Actions
PC092 Juillet 1986 Comment determiner la posologie optimale d un medicament FR
2025-09-15
No Actions
PJ070 Dusseldorf Local Division 9 April 2024 UPCCFI4522023 DE
2025-09-15
No Actions
PJ064 CJEU 28 July 2011 Generics UK c Synaptech galantamine C42709 GB
2025-09-15
No Actions
PC118 Overall 1994 Journal of Clinical Psychology Vol 50 pages 95 102 GB
2025-09-15
No Actions
PC039 Wikipedia page EDSS GB
2025-09-15
No Actions
PC152 Submissions in high resolution GB
2025-09-15
No Actions
PC097 Screenshots of patients testimonies online 2 2 FR
2025-09-15
No Actions
PC143 Chapter 33 Pymadin Paskov et al 1986 GB
2025-09-15
No Actions
PC080 website of the Foundation for Research into Multiple Sclerosis FR
2025-09-15
No Actions
PJ056 Santen C 673 18 GB
2025-09-15
No Actions
PC043 Goodman Diaporama Placebo Controlled Double blinded Dose Ranging Study of Fampridine SR in Multiple Sclerosis GB
2025-09-15
No Actions
PC150 4-Aminopyridine C5H6N2 CID 1727 PubChem GB
2025-09-15
No Actions
PC102 Clinical studies in 20 questions Atelier Presse Clinical trials LEEM 19 May 2011 FR
2025-09-15
No Actions
PC149 IQVIA Data unredacted version GB
2025-09-15
No Actions
PC032 Form S 1 Presentation GB
2025-09-15
No Actions
PJ060 Decision de la Chambre de recours de lOEB 13 septembre 2017 T023916 GB
2025-09-15
No Actions
PC093 Hayes et al 2003 Pharmacokinetics of an Immediate Release Oral Formulation of Fampridine 4 Aminopyridine in Normal
2025-09-15
No Actions
PJ074 Decision de la Chambre de recours de lOEB du 4 octobre 2004 T 111003 GB
2025-09-15
No Actions
PJ080 Munich Local Division 21 May 2024 UPCCFI432023 DE
2025-09-15
No Actions
PJ083 Fingolimod DE OLG Dusseldorf Appel 03082023 DE
2025-09-15
No Actions
PC119 Hamilton et al 1998 Olanzapine versus placebo and haloperidol quality of life and efficacy results on the North Am
2025-09-15
No Actions
PJ057 TJ Paris 12 mai 2021 RG 2153136 Cabazitaxel Sanofi c Teva FR
2025-09-15
No Actions
PC057 FDA Chapter I Food and Drug Administration Department of Health and Human Services Subchapter D Drugs for Human Us
2025-09-15
No Actions
PC114 Cook et al 1983 Design and analysis methods for longitudinal research Ann Rev Public health GB
2025-09-15
No Actions
PC072 Germany Teva 20230711 Revocation of patent EP 548 DE
2025-09-15
No Actions
PJ007 TJ Paris Ordonnance de refere 6 octobre 2022 RG 22 55799 Biogen c Viatris DMF FR
2025-09-15
No Actions
PC137 They are looking for a superpill for Alzheimers Technologies News Standard 2013 BG
2025-09-15
No Actions
PC019 European Medicines Agency Guidelines ICH Topic E4 November 1994 GB
2025-09-15
No Actions
Objection
2025-09-16
No Actions
Receipt
2025-09-16
No Actions
Receipt
2025-09-16
No Actions
Request for procedural order
2025-09-16
No Actions
Headnote-and-Keywords
2025-09-17
No Actions
Outcome of the Order
2025-09-17
No Actions
procedural order
2025-09-17
Receipt
2025-09-17
No Actions
EN pdf 1
2025-09-17
Receipt
2025-09-18
No Actions
PC154 IQVIA Agreement GB
2025-09-18
No Actions
PC149 IQVIA Data unredacted version GB
2025-09-18
No Actions
20250915 - Request v.def PDF-A signed
2025-09-18
No Actions
PC149 IQVIA Data unredacted version GB
2025-09-18
No Actions
action.issueOrder.order
2025-09-24
No Actions
Order
2025-09-24
No Actions
Cover sheet
2025-09-25
No Actions
Exhibit
2025-09-25
No Actions
Exhibit
2025-09-25
No Actions
Exhibit
2025-09-25
No Actions
Exhibit
2025-09-25
No Actions
Exhibit
2025-09-25
No Actions
Other document
2025-09-25
No Actions
Receipt
2025-09-25
No Actions
Cover sheet
2025-09-25
No Actions
Exhibit
2025-09-25
No Actions
Other document
2025-09-25
No Actions
Receipt
2025-09-25
No Actions
action.communication.general
2025-09-25
No Actions
action.communication.general
2025-09-26
No Actions
Cover sheet
2025-10-01
No Actions
Application
2025-10-01
No Actions
Receipt
2025-10-01
No Actions
Cover sheet
2025-10-01
No Actions
Statement of reply
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Exhibit
2025-10-01
No Actions
Receipt
2025-10-01
No Actions
action.issueOrder.order
2025-10-02
No Actions
Order
2025-10-02
No Actions
Cover sheet
2025-10-02
No Actions
Application
2025-10-02
No Actions
Receipt
2025-10-02
No Actions
action.issueOrder.order
2025-10-02
No Actions
Order
2025-10-02
No Actions
Cover sheet
2025-10-02
No Actions
Application
2025-10-02
No Actions
Receipt
2025-10-02
No Actions
Cover sheet
2025-10-05
No Actions
Application
2025-10-05
No Actions
Receipt
2025-10-05
No Actions
action.communication.general
2025-10-06
No Actions
action.communication.general
2025-10-06
No Actions
action.issueOrder.order
2025-10-07
No Actions
Order
2025-10-07
No Actions
action.issueOrder.order
2025-10-07
No Actions
Order
2025-10-07
No Actions
Cover sheet
2025-10-09
No Actions
Fee
2025-10-09
No Actions
Application
2025-10-09
No Actions
Other document
2025-10-09
No Actions
Proof of payment
2025-10-09
No Actions
Receipt
2025-10-09
No Actions
action.communication.general
2025-10-10
No Actions
Cover sheet
2025-10-14
No Actions
Fee
2025-10-14
No Actions
Application
2025-10-14
No Actions
Proof of payment
2025-10-14
No Actions
Receipt
2025-10-14
No Actions
action.issueOrder.order
2025-10-29
No Actions
Order
2025-10-29
action.communication.general
2025-11-21
No Actions
Order
2025-11-21
action.issueDecision.decision
2025-11-21
No Actions
Final Order
2025-11-21
No Actions
action.phaseChange.oralPhaseClose
2025-11-21
No Actions
action.phaseChange.writtenPhaseClose
2025-11-21
No Actions
action.communication.general
2025-11-28
No Actions
Cover sheet
2025-11-28
No Actions
Application document Claimant
2025-11-28
No Actions
Receipt
2025-11-28
No Actions
EN pdf 1
2026-02-19
action.phaseChange.caseClose
2026-06-08
No Actions